Navigation Links
Diopsys Receives CE Mark for its VEP Vision Testing Systems

PINE BROOK, N.J., Nov. 2, 2011 /PRNewswire/ -- Diopsys, Inc. announced today that its Visual Evoked Potential (VEP) Vision Testing Systems have been awarded the CE mark. The company has begun a roll-out of its patented vision testing devices to EU customers.

Diopsys completed a rigorous inspection of its total quality system in order to qualify for CE status.  "Having the CE mark opens many opportunities for us to provide clinicians and patients across the EU access to our advanced VEP technology," says Joseph Fontanetta, CEO of Diopsys, "Our VEP devices are designed to be used in an office setting and our patented technology overcomes many limitations of traditional VEP devices. Testing times are much faster than older VEP devices and our reports are easier to interpret. We are proud to bring an operator-friendly, objective, functional vision test to patients in need."

Diopsys is the developer and marketer of the Diopsys® NOVA-VEP Vision Testing Systems utilized by ophthalmologists and optometrists to aid in the detection, diagnosis and treatment of vision disorders, including glaucoma, a disease affecting millions globally. The company has also developed and markets the Enfant® Pediatric VEP Vision Testing System, a device used to test for visual deficits, including amblyopia, in children as young as six months of age.

Visual Evoked Potentials (VEPs) are electrical signals that are a measure of the electrophysiological activity at the visual cortex. VEP results are a representation of the functional integrity of all levels of the visual pathway including the eye, retina, optic nerve, and visual cortex. This technology has been used for a variety of applications that involve neuro-visual disorders such as glaucoma, amblyopia, multiple sclerosis and diabetic retinopathy, among many others.(1,2,3,4 )

About Diopsys

Diopsys, Inc. ( is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing equipment utilizing Visual Evoked Potential (VEP) technology.


1. Prata TS, Lima VC, De Moraes CG, Trubnik V, Derr P, Liebmann JM, Ritch R, Tello C. Short Duration Transient Visual Evoked Potentials in Glaucomatous Eyes. J Glaucoma. 2011 May 10. [Epub ahead of print]

2. Simon J, Siegfried J, Mills M, Calhoun J, Gurland J. A New Visual Evoked Potential System for Vision Screening in Infants and Young Children. Journal of AAPOS. 8.6 (2004): 549-554.

3. Garcia-Martin E, Pueyo V, Ara JR, Almarcegui C, Martin J, Pablo L, Dolz I, Sancho E, Fernandez FJ. Effect of optic neuritis on progressive axonal damage in multiple sclerosis patients. Mult Scler. 2011 Jul;17(7):830-7. Epub 2011 Feb 7.

4. Parisi V, Uccioli L. Visual electrophysiological responses in persons with type 1 diabetes. Diabetes Metab Res Rev. 2001 Jan-Feb;17(1):12-8.

SOURCE Diopsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diopsys, Inc. Launches New Website for Doctors and Patients,
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):